$43.06
+2.8%Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Executive Vice President & Chief Financial Officer
Compensation
$1,017,934
Executive Vice President & Chief Operating Officer
Compensation
$292,901
Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary
Compensation
$924,219
Founder, Executive Chairman, President & Chief Executive Officer
Compensation
$2,165,365
Senior Vice President & Chief Information Officer
Senior Vice President & Chief People Officer
Senior Vice President & Chief Technology Officer
Senior Vice President of Global Operations
Senior Vice President of Investor Relations
Vice President, Chief Accounting Officer & Corporate Controller
During the last 12 months, insiders have sold $3.06M worth of OMCL shares, with no buying activity reported.
0
0.00
15.5K
607.61K
-608K
-$608K
0
0.00
10.6K
471.98K
-472K
-$472K
0
0.00
41.7K
1.51M
-1.5M
-$1.51M
0
0.00
14.8K
467.81K
-468K
-$468K
No buying activity
Manley Corey J
Officer: Evp&Chief Legal/Admin Officer
$1.53M
Lipps Randall A
Director, Officer: Chairman, President And Ceo
$1.28M
Njoku Nnamdi
Officer: Evp, Chief Operating Officer
$134K
Etta Nchacha
Officer: Evp & Cfo
$112K
Strong bearish signal with $3.06M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
OMCL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | May 19, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 03, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 04, 2024 | May 21, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 06, 2023 | April 06, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 08, 2021 | May 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 07, 2020 | May 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 01, 2019 | May 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 02, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 17, 2017 | May 23, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.